As for the combination therapy of PARPi and TMZ, SLFN11 expression appears to mainly correlate with sensitivity to PARPi treatment, however, in mesothelioma cell lines and SCLC in vivo models SLFN11 expression also correlated with increased response to PARPi and TMZ combination treatment (Lok et al. 2017; Rathkey et al. 2020). Here, SLFN11 is linked to small cell lung carcinoma.